Form 4: Xencor Director Raymond Deshaies Granted Over 110,000 Stock Options

Xencor Inc. Director Raymond Joseph Deshaies was granted 110,422 stock options with an exercise price of $8.32, vesting over three years.

Summary

• Raymond Joseph Deshaies, a Director of Xencor Inc. (XNCR), was granted 110,422 stock options.
• The stock options have an exercise price of $8.32 per share.
• The earliest transaction date for this grant is July 31, 2025.
• The options are set to expire on July 31, 2035.
• The vesting schedule dictates that one-third of the shares subject to the option will vest and become exercisable on July 31, 2026.
• The remaining shares will vest in equal monthly installments over the subsequent 24 months.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of an insider stock option grant, which is generally a neutral to slightly positive event as it aligns director interests with the company's long-term performance. It does not contain information that would significantly alter the company's financial outlook or operations.

Positives

• The grant of stock options to a director aligns their interests with the long-term performance of the company and its shareholders.
• The transaction was conducted under a Rule 10b5-1(c) plan, indicating a pre-planned and transparent transaction.

Future Outlook

The vesting schedule for the granted stock options extends over the next three years, indicating a long-term incentive for the director.

Industry Context

This filing is a standard disclosure of an insider equity grant, common in the biotechnology and pharmaceutical industries to incentivize and retain key personnel, including directors, by aligning their financial interests with the company's long-term success.

Comparison to Industry Standards

• The grant of stock options to directors is a common practice across publicly traded companies, including those in the biotechnology sector, to align director incentives with shareholder value.
• The vesting schedule of three years is typical for such equity grants, providing a long-term retention mechanism.
• The use of a Rule 10b5-1(c) plan is a standard corporate governance practice for insiders to manage their equity transactions in a compliant and transparent manner, similar to practices at comparable biotech firms like Amgen Inc. (AMGN) or Gilead Sciences, Inc. (GILD) when their executives or directors receive equity awards.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon exercise of options, but also improved alignment of director's interests with shareholder value creation.
• Employees: No direct impact mentioned for general employees.

Next Steps

• The stock options will begin vesting on July 31, 2026, with subsequent monthly vesting installments over the following 24 months.

Key Dates

Keywords

Xencor Inc, XNCR, Stock Options, Director Compensation, Insider Transaction, SEC Form 4, Equity Grant, Biotechnology, Pharmaceuticals